MICROPLATE READERS


Modified viruses are used as viral vectors (or ‘carriers’) in gene therapy


VICTORIESVector


Breaking the vector characterisation bottleneck with macro mass photometry


V


iral vectors play a pivotal role in the advancement of vaccines and cell and gene therapies (CGTs), serving


as versatile therapeutic delivery vehicles. Vector characterisation is an important analytical step of the therapeutic production pipeline, but can be a longwinded process, requiring extensive biological (e.g., PCR), cell- based (e.g., infectivity assays), and


26 www.scientistlive.com


physicochemical (e.g., analytical ultracentrifugation (AUC)) testing.


LIMITATIONS OF CHARACTERISATION TECHNIQUES Conventional characterisation techniques bring limitations: Cell- based vector analysis takes days to perform, while more rapid approaches, like nanoparticle tracking analysis (NTA), provide limited characterisation data. Along with a paucity of in-process analysis tools, these obstacles create a significant bottleneck at the vector characterisation stage for vaccine and CGT programs.


In light of the demand for new


innovations to improve the accuracy and speed of vector analysis, macro mass photometry has emerged as a promising solution. Using light scattering to analyse particles, this novel method unlocks a host of valuable vector characterization capabilities, including rapid and accurate determination of full/empty capsid ratios, sample purity and more.


UNDERSTANDING MACRO MASS PHOTOMETRY Macro mass photometry interrogates two parameters in parallel: particle scattering contrast (a proxy for mass)


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60